GRN and frontotemporal dementia: Several other therapies targeting PGRN elevation are also being explored in earlier stages of clinical testing, including phase I/II open-label studies of gene therapy for FTD-GRN in the PROCLAIM, upliFT-D, and ASPIRE-FTD clinical trials.